Loading...
•
Sep 30, 2023
United Therapeutics Q3 2023 Earnings Report
United Therapeutics reported record quarterly revenue and double-digit revenue growth, driven by commercial execution and innovative research.
Key Takeaways
United Therapeutics reported an 18% year-over-year increase in total revenues for Q3 2023, reaching $609.4 million compared to $516.0 million in Q3 2022. Net income also increased by 12% to $267.6 million.
Total revenues grew by 18% year-over-year to $609.4 million.
Net income increased by 12% to $267.6 million.
Tyvaso DPI sales increased significantly following its commercial launch.
The company is progressing with clinical trials for nebulized Tyvaso and ralinepag, with potential data in 2025.
Revenue by Segment
Forward Guidance
United Therapeutics anticipates achieving a $4 billion annual revenue run rate by mid-decade and expects growth in product utilization by PH-ILD patients due to recent field force expansion. Clinical trials for nebulized Tyvaso and ralinepag may generate data in 2025.
Positive Outlook
- Anticipated $4 billion annual revenue run rate by mid-decade.
- Expected growth in product utilization by PH-ILD patients.
- Potential data generation from TETON 1, TETON 2, and ADVANCE OUTCOMES clinical trials in 2025.
- Focus on innovating for unmet medical needs of patients.
- Commitment to developing novel pharmaceutical therapies and technologies.
Challenges Ahead
- Risks and uncertainties described in periodic reports filed with the SEC.
- Potential for actual results to differ materially from anticipated results.
- Cautionary statements and risk factors in periodic reports.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...